Allergan acquires EarFold ear implant assets

Allergan (NYSE: AGN) said today it agreed to acquire Northwood Medical’s EarFold implant technology designed to correct prominent ears, with or without asymmetry, in patients 7 years or older. The device from London-based Northwood is a small implantable strip of nitinol metal alloy that is inserted under the skin and grips ear cartilage, enhancing or creating the shape of the anti-helical fold and reducing ear prominence, the company said. “EarFold technology adds another innovative product to our medical aesthetics product portfolio, especially for the plastic surgeons we serve today, and has the potential to expand the number of patients interested in corrective surgery as it provides an alternative treatment that may appeal to those who have been reluctant to undergo traditional surgical procedures. Many of Allergan’s plastic surgery customers currently perform otoplasty procedures, emphasizing our commitment to serving the unmet needs and practice of plastic surgery,” Allergan international brands prez Paul Navarre said in a press release. The EarFold device won CE Mark approval in the European Union in April this year, Allergan said. Upon the closure of the acquisition, Allergan intends to commercialize the product “widely across Europe,” and will continue to explore regulatory pathways and requirements to commercialize the device in other countries, including the U.S. Also following closure of the deal, Allergan will &...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Cosmetic/Aesthetic Mergers & Acquisitions Allergan Inc. Source Type: news

Related Links:

Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conditions:   Open-Angle Glaucoma;   Ocular Hypertension Intervention:   Drug: Bimatoprost SR Sponsor:   Allergan Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glaucoma Intervention:   Device: XEN Group Sponsor:   Allergan Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We describe the case of an 84-year-old white gentleman who underwent right eye XEN implantation for refractory primary open-angle glaucoma who subsequently developed persistent hypotony secondary to an overfiltering bleb. The complication was successfully treated with a modified transconjunctival bleb compression suture technique. To our knowledge, this has not been previously described in the literature and may help the glaucoma specialist deal effectively and relatively noninvasively with this rare but potentially challenging minimally invasive glaucoma surgery complication.
Source: Journal of Glaucoma - Category: Opthalmology Tags: Online Articles: Case Report/Small Case Series Source Type: research
Abstract The prevalence of allergic diseases has been increasing recently. Allergy has various symptoms. Allergic eye diseases (seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis, contact blepharoconjunctivitis) are common in atopic patients. Treatment options for allergic conjunctivitis include local and systemic antihistamines, mast cell stabilizers, dual-action agents, vasoconstrictors and corticosteroids. Treatment seems easy, but inappropriate therapy - in extreme cases - can lead to vision loss. Corticosteroid eyedrops prov...
Source: Orvosi Hetilap - Category: General Medicine Authors: Tags: Orv Hetil Source Type: research
More News: Allergy | Anesthesia | Anesthesiology | Clinical Trials | Funding | Glaucoma | Medical Devices | Mergers and Aquisitions | Otoplasty | Plastic Surgery | Skin | Training | Universities & Medical Training